Navigation Links
Mayo Clinic Proceedings: Gabapentin opens window of communication
Date:6/16/2010

ROCHESTER, Minn. -- For patients with quadriplegia, mutism and lower cranial nerve paralysis (locked-in syndrome), their only means of interacting with others is through vertical gaze and upper eyelid movements, using eye-coded communication strategies.

In the June issue of Mayo Clinic Proceedings, researchers from Italy describe four patients with locked-in syndrome who also had dancing eye syndrome (opsoclonus-myoclonus syndrome). Because these patients' eyes spontaneously and continuously oscillated in a variety of directions beyond their control, they could no longer interact with family members, physicians or other people.

The lead author, Francesca Pistoia, M.D., University of L'Aquila, Italy, reports that a decision was made to treat these patients with daily continuous gabapentin therapy based on a previous successful experience. Gabapentin was started as a single 300 mg dose on the first day followed by 600 milligrams per day in divided doses on the second day. In two of the patients, this dosage reduced ocular symptoms, and communication and quality of life improved. For the other two patients, the dose was further increased, with the best response achieved with a daily 1,200 mg dose.

In all four patients, attempts to stop treatment resulted in recurrence of dancing eye symptoms six hours after the last dose. Thus, gabapentin use was promptly resumed. Researchers found none of the patients experienced adverse effects from the treatment.

In an accompanying editorial, Joseph Sirven, M.D., Mayo Clinic neurologist, discusses the off-label use of gabapentin, which was approved by the U.S. Food and Drug Administration in 1994 for use as an adjunctive medication to control partial seizures. Dr. Sirven writes, "Ironically, despite the fact that the drug was invented and synthesized for its use in seizure prevention, its smallest market today is epilepsy and seizures."

"The study by Pistoia and colleagues has a potential profound impact for treatment of patients with locked-in syndrome and opsoclonus-myoclonus syndrome," writes Dr. Sirven. "Because this neurologic condition is so rare, small observational studies serve as the main source of clinical evidence and could be the cornerstone for clinical practice with no other evidence."


'/>"/>

Contact: Rebecca Finseth
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. BRAF inhibitor shows promising preclinical activity against melanoma
2. Free Clinics Play Important Role for Uninsured in U.S.
3. Sunrise Services Wins the Gold in Medisoft Clinical Sales Contest
4. Sanford Health Announces Sanford Children's Clinic in Klamath Falls, OR
5. Sharron Davies opens new respiratory research clinic
6. European patient survey add weight to expert call for greater clinical consensus on BTCP
7. FDA approves first human neural stem cell clinical trial to treat brain tumors
8. Antibody therapy lengthens survival of metastatic melanoma patients in large clinical trial
9. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
10. Fox Chase clinical trial tests first of its kind antibody
11. Launching Five Clinics on Wheels This Year, Ronald McDonald House Charities Celebrates Ten Years of the Ronald McDonald Care Mobile Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
(Date:2/10/2016)... ... February 10, 2016 , ... A national ergonomics pioneer ... Expo event March 9-11, 2016. Hosted by Ohio's Bureau of Worker's Compensation, the ... the longest running and largest worker's compensation event in Ohio, organizers of the ...
(Date:2/10/2016)... West Palm Beach, Florida (PRWEB) , ... February ... ... Golf & Country Club) announced that it has been awarded the prestigious Distinguished ... of the World award program conducted by BoardRoom magazine, one of the most ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has ... readily available to physicians. The integration will enable Allscripts users to post ... via Everseat’s free mobile app. , The partnership gives Everseat substantial added power ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... ... their revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine ... provide a solution that ensures the integrity of biological samples while operating at ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 9, 2016  Until recently, the ... surgery or liposuction. Thankfully, the FDA approved the non-invasive ... to death. Coolsculpting was originally approved in 2010 for ... thighs and now the chin. With this add-on approval, ... can use a smaller applicator, the CoolMini, to address ...
(Date:2/10/2016)... 2016 On Tuesday, February 9th, the ... with its Arthritis Advisory Committee to discuss ... & Johnson,s Remicade and most likely the ... U.S. The Biologics Prescribers Collaborative (BPC) along ... for Patient Access, American Association of Clinical ...
(Date:2/10/2016)... 2016 CTI BioPharma Corp. (CTI BioPharma) ... regarding the clinical studies being conducted under the ... Following the issuance of the Company,s February 8, ... issued by the U.S. Food and Drug Administration ... an oral communication from the FDA followed by ...
Breaking Medicine Technology: